Acambis will be responsible for the advancement of its Phase II candidate as well as filing for approval.
Sanofi pasteur inked a deal related to development and marketing of Acambis’ ChimeriVax™-West Nile vaccine. Acambis stands to earn over $80 million in this exclusive global collaboration.
ChimeriVax-West Nile is in a Phase II safety, tolerability, and immunogenicity trial in the U.S. in adults over 41 years. Acambis will continue development and will also be responsible for the filing of a license application in the U.S.
Sanofi pasteur will initially pay $10 million. Acambis will be eligible for development funding as well as $70 million in pre- and post-marketing milestone fees based on product approval and sales in the U.S. If the vaccine receives registration in other countries, the company will receive additional post-marketing milestone payments. Acambis will also get royalties on global net sales.
“This vaccine candidate is the most promising in the industry and would help meet a growing public health need,” commented Wayne Pisano, president and CEO of sanofi pasteur.
